(b)(2) or not to be, that is the question
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they…
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they…
In this interview filmed at CPHI Barcelona, Nanoform CCO Christian…
Nanoparticle formulations are a key tool for addressing drug development…
In order to truly benefit patients and the world, it…
Our talented team presented their research at AAPS PharmSci 360…
How can nanoparticle engineering build a more sustainable pharmaceutical value…
Nanoforming improves bioavailabiliy by increasing the specific surface area of…
Presented at the 2023 Controlled Release Society Annual Meeting by…